Live Q&A: A Deeper Dive into NASH Diagnosis and Treatment: An Augmented Reality Experience
Premiere Date: Tuesday, February 23, 2021This activity offers CE credit for:
- Physicians (CME)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, February 23, 2022
Note: Credit Is No Longer Available
 | Mazen Noureddin, MD, MHSc Director, Fatty Liver Program Karsh Division of Gastroenterology and Hepatology Comprehensive Transplant Center Cedars-Sinai Medical Center Los Angeles, CA |
Obesity and diabetes are on the rise, leading to an increased prevalence of non-alcoholic fatty liver disease (NAFLD), which in some cases may progress to non-alcoholic steatohepatitis (NASH). NAFLD affects approximately 30% of the U.S. population, with NASH effecting about 5%. NASH comes with a significant risk of progression to advanced liver fibrosis, cirrhosis, and hepatocellular carcinoma. Disease models project that the number of individuals with end-stage liver disease will double - or possibly triple - by 2030.
With the majority of high-risk patients first seen in the primary care setting, it is imperative that internists and primary care physicians identify patients at risk for NASH. Although liver biopsy was previously the best test for identifying the critical endpoints of NASH, several noninvasive, yet effective, tests have been developed recently that have the potential to be implemented in primary care settings. While currently there are no approved treatments for NASH, novel targeted therapies are being studied in phase III clinical trials, some of which have shown promising results.
This live question and answer session is your opportunity to ask questions based on the CME Outfitters virtual symposium where expert faculty focused on NASH, particularly on risk stratification, diagnosis, and emerging targeted therapies. To view the full activity ahead of this live Q&A, click here
At the end of this CE activity, participants should be able to:
- Identify risk factors associated with NAFLD and NASH.
- Utilize appropriate noninvasive tests for the identification of NASH in patients with NAFLD.
- Evaluate novel therapeutic targets and clinical evidence on emerging therapies for NASH.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Identify risk factors associated with NAFLD and NASH.
- Describe appropriate noninvasive tests for the identification of NASH in patients with NAFLD.
- Evaluate novel therapeutic targets and clinical evidence on emerging therapies for NASH.
Supported by an educational grant from Intercept Pharmaceuticals, Inc.
Internists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this live activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hour (0.05 CEUs). Universal Activity Number:
Live: 0376-0000-21-009-L01-P
Type: knowledge-based
Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME or a recognized state medical society.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
Credit request forms and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately. This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Noureddin reports that he receives research support from Allergan; Bristol-Myers Squibb Company; Conatus Pharmaceuticals Inc.; Enanta Pharmaceuticals, Inc.; Galectin Therapeutics Inc.; Galmed Pharmaceuticals; GENFIT; Gilead Sciences, Inc.; Novartis; Shire and Zydus Pharmaceuticals, Inc. He is on the advisory board or speakers bureau for Abbott; Allergan; Blade Therapeutics; Echosens North America; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Novartis; OWL; Pfizer Inc.; Roche Diagnostics, North America; and Siemens. He is a stock shareholder (directly purchased) of Ananetos and Viking Therapeutics, Inc.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty has been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MMQ-099-022321-60
